

NEW: PHARMEUROPA SCIENTIFIC NOTES

As from Pharmeuropa 17.4, Scientific Notes are no longer published in Pharmeuropa, but are published in a new publication called Pharmeuropa Scientific Notes.

Articles published in Pharmeuropa Scientific Notes are indexed in the PubMed database of the National Library of Medicine, available on the internet site (www.ncbi.nlm.nih.gov).

The first edition of Pharmeuropa Scientific Notes (Pharmeuropa SN 2005-1) became available in August 2005.

This issue is included in the subscription to Pharmeuropa, and is not available separately.

SCIENTIFIC NOTES 2005-1

- Few Bicyclic Acetals at Reducing End of Low-Molecular-Weight Heparins: Might they Restrict Specification of Pharmacopoeia?
- The Control of Impurities in Chlortalidone Using a Reversed-Phase Stationary Phase
- Factor VIII Test in Reference Preparations: Compensation for Different Dilutions
- The Control of Impurities in Amitriptyline Hydrochloride Using a Reversed-Phase Hybrid Stationary Phase
- A Precise Colour Determination Method for Tablets - an Application of Instrumental Colour Measurement in the Pharmaceutical Development
- Development of an *in vivo* Test Procedure for the Ease of Breaking of Scored Tablets
- Chromogenic Assay of Human Coagulation Factor VIII: Statistical Comparison of 2 Working Dilution Procedures
- Impurity Profile of Amino Acids?
- Batch Variability of Bacitracin: HPLC versus MEKC
- Quality Criteria of Homoeopathic Mother Tinctures: Considerations Regarding Suitable Tests for Homoeopathic Monographs
- *Instructions for Authors*

Available now (English only)

For prices and ordering information please consult the catalogue on our internet site <http://book.pheur.org>

MADAGASCAR, ISRAEL AND BRAZIL: THREE NEW OBSERVERS TO THE EUROPEAN PHARMACOPOEIA COMMISSION

The states of Madagascar (March 2005), Brazil and Israel (June 2005) requested and obtained observer status by the European Pharmacopoeia Commission in 2005.

The decision of the European Pharmacopoeia Commission was voted unanimously by the delegates from the member countries, thus allowing collaboration to develop between the authorities of the Pharmacopoeia throughout the world.

This status permits observers to participate regularly in the work of the European Pharmacopoeia and to facilitate exchanges of knowledge and to share know-how, thus contributing to improvement of the quality control of medicines at a global level. To date the European Pharmacopoeia Commission has 35 members and 18 observers.

Member parties to the European Pharmacopoeia Commission: Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, the Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Norway, Portugal, Romania, Serbia and Montenegro, Slovakia, Slovenia, Spain, Sweden, Switzerland, 'the former Yugoslav Republic of Macedonia', Turkey, the United Kingdom, and the European Union.

Observers to the European Pharmacopoeia Commission: Albania, Georgia, Poland and Ukraine in Europe and 13 other countries in the world: Algeria, Australia, Brazil, Canada, China, Israel, Madagascar, Malaysia, Morocco, Senegal, Syria, Tunisia, United States of America, and WHO (World Health Organisation).